Drugs / Pimonidazole
Pimonidazole
also known as
Hypoxyprobe-1 · pimonidazole-HCl · NSC-380540 · PD 126675 · Pimonidazol · Pimonidazole hydrochloride · pimonidazole hydrochloride (HCl) · RO 03-8799
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03718650 | Apr 2021 → Apr 2022 | malignant pancreatic neoplasm, pancreatic exocrine neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 11 trial | ||||||
| Phase 1 | NCT03410420 | Sep 2018 → Sep 2025 | thoracic aortic aneurysm | Thomas Gleason | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03181035 | Jan 2018 → Sep 2024 | tongue cancer | Sunnybrook Health Sciences Centre | Suspended | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02414048 | Apr 2015 → Oct 2022 | head and neck cancer | Marius Gustav Bredell | Unknown | No outcome recorded |
| Phase 2 | NCT02061007 | Oct 2014 → Feb 2016 | melanoma, skin cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00374517 | Sep 2006 → Feb 2010 | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03418818 | Mar 2018 → Oct 2028 expected | sarcoma | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01992042 Background | Feb 2014 → Oct 2016 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| — | NCT02095249 Background | Sep 2014 → Jan 2028 expected | prostate cancer | University Health Network, Toronto | Active not recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pimonidazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01992042 ↗ |
| Known as | Hypoxyprobe-1 | “This is a prospective study designed to determine the safety and value of Hypoxyprobe-1 (pimonidazole hydrochloride (-HCl)) to detect levels of tissue hypoxia in patients...” NCT03410420 ↗1“Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).” NCT02061007 ↗ |
| Known as | NSC-380540 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58752 ↗ |
| Known as | PD 126675 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58752 ↗ |
| Known as | Pimonidazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL58752 ↗ |
| Known as | Pimonidazole hydrochloride | “This is a prospective study designed to determine the safety and value of Hypoxyprobe-1 (pimonidazole hydrochloride (-HCl)) to detect levels of tissue hypoxia in patients...” NCT03410420 ↗ |
| Known as | pimonidazole hydrochloride (HCl) | “a substance called pimonidazole hydrochloride (HCl) it builds up specifically in hypoxic areas” NCT03181035 ↗ |
| Known as | pimonidazole-HCl | “This pilot study will use pimonidazole-HCl, a compound that is retained by hypoxic cells and that has been used for detection of tissue hypoxia in human since the early 2000s.” NCT03410420 ↗1“a single dose of oral pimonidazole-HCl before having surgery to remove their cancer” NCT03181035 ↗ |
| Known as | RO 03-8799 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58752 ↗ |
| Modality | Diagnostic / imaging agent | “using an in vivo hypoxia-imaging marker, pimonidazole hydrochloride” NCT00374517 ↗ |
| Route | Intravenous | “Infusion of pimonidazole through a vein in the arm 24 hours before surgery.” NCT00374517 ↗ |